Why Novavax's Stock Is Surging Today

What happened

Shares of the clinical-stage vaccine developer Novavax (NASDAQ: NVAX) rose by more than 11% on heavy volume in premarket trading today. What’s driving this double-digit move higher?

Novavax’s shares are surging in response to a positive midstage data readout for the company’s experimental flu vaccine, NanoFlu. The company reported that NanoFlu produced a superior immune response in elderly adults when compared to the current standard of care, Sanofi ‘s (NYSE: SNY) Fluzone High-Dose.

Doctor holding out a signboard that reads "flu vaccination".

Image Source: Getty Images.

So what

If NanoFlu can replicate these positive results in a pivotal trial, Novavax will have a potential megablockbuster product on its hands. The U.S. flu vaccine space, after all, is projected to grow into a marketplace worth $3 billion a year  by 2024. Moreover, Sanofi’s Fluzone High-Dose vaccine has some well-documented shortcomings that make it extremely vulnerable to potential competitors.

EvaluateGroup — a top biopharma analyst group — has NanoFlu pegged as one of the most valuable vaccines currently under development. That fact alone could transform Novavax into a red-hot buyout candidate.

Now what

With these positive midstage results in hand, Novavax plans on holding a meeting with the Food and Drug Administration about the vaccine’s forthcoming pivotal trial before the middle of this year. If this regulatory meeting goes off without a hitch, the company plans on advancing NanoFlu into a late-stage trial in late 2019 — although there is an outside chance that regulators will permit an accelerated regulatory filing, according to the company.

What does all this mean? In brief, Novavax has a good shot at bringing a high-value flu vaccine to market as soon as 2021. In the interim, the company is also expected to release the late-stage results for its respiratory syncytial virus (RSV) vaccination study in pregnant women within the next few weeks. Novavax is thus off to a great start in 2019, but the best could be yet to come.

10 stocks we like better than Sanofi

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Sanofi wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 14, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.

Wealth Empire Newsletter
Register now for free updates and alerts

Subscribe By

Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.